<DOC>
	<DOCNO>NCT00015665</DOCNO>
	<brief_summary>This protocol provide emergency treatment experimental anti-fungal drug voriconazole patient life-threatening invasive fungal infection . The increase number patient whose immune function suppress chemotherapy , tissue organ transplantation , HIV infection lead increase fungal infection . New drug need combat infection patient respond tolerate standard treatment . Patients primary NIH protocol invasive life-threatening fungal infection respond currently available treatment tolerate treatment may eligible study . Participants blood test physical examination receive voriconazole . They receive voriconazole twice day either infusion vein tablets take mouth . Adult patient ask provide blood sample time first dose voriconazole use develop test measure voriconazole concentration blood . Patients evaluate 10 day start treatment least every 4 week symptom check blood test .</brief_summary>
	<brief_title>Emergency Use Voriconazole Patients With Life-Threatening Invasive Fungal Infections</brief_title>
	<detailed_description>The increase number immunosuppressed patient result aggressive chemotherapy , transplantation , HIV infection lead increase incidence invasive fungal infection . Moreover , despite availability newer , less toxic preparation Amphotericin B azole antifungal fluconazole itraconazole , invasive mycoses remain therapeutic challenge . Voriconazole new triazole show phase II study active Aspergillus sp . Its side effect profile benign , comparable FDA approve triazoles . In vitro study also show voriconazole broad spectrum range opportunistic endemic fungi . In addition , availability intravenous oral formulation add potential advantage therapy infection usually require long course antifungal . In study , voriconazole use salvage therapy patient unable tolerate fail antifungal therapy . Because abundance immunocompromised patient center , believe protocol ready enrollment would mitigate delay crucial moment . We seek enroll treat 40 patient 3 year period .</detailed_description>
	<mesh_term>Emergencies</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Voriconazole</mesh_term>
	<criteria>INCLUSION CRITERIA : All subject must prove fungal infection resistant standard therapy , patient significantly intolerant . ( Intolerance must include sign intolerance fever , rigor , laboratory abnormality , well subjective symptom ) . Children eligible . EXCLUSION CRITERIA : AST , ALT great 10x upper limit normal Previous hypersensitivity azole antifungal Concomitant Rifampin , carbamazepine , barbiturates great 3 day drug 14 day prior treatment voriconazole</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2003</verification_date>
	<keyword>Fungal</keyword>
	<keyword>Immunodeficiency</keyword>
	<keyword>Infection</keyword>
	<keyword>Refractory</keyword>
	<keyword>Severe</keyword>
	<keyword>Fungal Infections</keyword>
</DOC>